Eloxx Pharmaceuticals Inc
F:3970
Eloxx Pharmaceuticals Inc
Other Items
Eloxx Pharmaceuticals Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eloxx Pharmaceuticals Inc
F:3970
|
Other Items
$258k
|
CAGR 3-Years
-82%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Items
-$18.8B
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-16%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Items
-$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
-14%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Items
$1.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Items
-$9.6B
|
CAGR 3-Years
-156%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Items
-$123m
|
CAGR 3-Years
46%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Eloxx Pharmaceuticals Inc
Glance View
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2012-11-23. The firm is focused on developing ribonucleic acid (RNA)-modulating drug candidates, each designed to be a eukaryotic ribosomal selective glycoside (ERSG), formulated to treat rare and ultra-rare premature stop codon diseases. The firm's lead product candidate, ELX-02, is a small molecule designed to restore production of full-length functional proteins. ELX-02 is in clinical development for systemic administration for cystic fibrosis. The firm is also conducting investigational new drug (IND)-enabling preclinical studies of ERSG compounds for autosomal dominant polycystic kidney disease (ADPKD) and in rare inherited retinal disorders (IRDs) by intravitreal administration with an initial focus on Usher Syndrome. Its preclinical candidate pool consists of a library of ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.
See Also
What is Eloxx Pharmaceuticals Inc's Other Items?
Other Items
258k
USD
Based on the financial report for Sep 30, 2023, Eloxx Pharmaceuticals Inc's Other Items amounts to 258k USD.
What is Eloxx Pharmaceuticals Inc's Other Items growth rate?
Other Items CAGR 5Y
39%
The average annual Other Items growth rates for Eloxx Pharmaceuticals Inc have been -82% over the past three years , 39% over the past five years .
